US equities
|
NVDA
$238.90
▲+2.12%
SPCX
$171.09
▲+7.63%
MU
$1,063.96
▼-1.02%
TSLA
$378.73
▲+2.20%
WBD
$30.95
▲+0.03%
MSFT
$525.18
▲+1.48%
AAPL
$332.89
▼-0.24%
META
$741.90
▲+1.90%
NVDA
$238.90
▲+2.12%
SPCX
$171.09
▲+7.63%
MU
$1,063.96
▼-1.02%
TSLA
$378.73
▲+2.20%
WBD
$30.95
▲+0.03%
MSFT
$525.18
▲+1.48%
AAPL
$332.89
▼-0.24%
META
$741.90
▲+1.90%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Elutia, Inc. - Class A Common Stock
(NQ:
ELUT
)
0.8216
+0.0429 (+5.51%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Elutia, Inc. - Class A Common Stock
Cellution Biologics Completes Acquisition of SimpliDerm® from Elutia Inc.
August 18, 2026
Acquisition expands Cellution Biologics’ human tissue-based portfolio and marks its entry into the U.S. reconstructive surgery market
From
Cellution Biologics
Via
GlobeNewswire
A Reno Biotech Just Rang the Nasdaq Bell — Here’s Why the Whole Regenerative-Medicine Tape Is Worth Watching
May 22, 2026
Issued on behalf of Conexeu Sciences Inc.
From
World Street Intelligence
Via
GlobeNewswire
TELA Bio Announces Strategic Board Refreshment with Four Highly Experienced Commerical Leaders to Accelerate Growth and Drive Path to Profitability; The Company Also Reports Preliminary First Quarter 2026 Revenues
April 30, 2026
From
TELA Bio, Inc.
Via
GlobeNewswire
SWK Holdings Provides Portfolio Update
October 17, 2024
Via
ACCESSWIRE
SWK Holdings Highlights Recent Achievements and Provides Portfolio Update
July 17, 2024
Via
ACCESSWIRE